NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug OLN324 tested for wet AMD and diabetic swelling
Disease control CompletedThis early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New eye drug shows promise in battle against blinding disease
Disease control CompletedThis study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. 488 adults aged 50-85 with active disease received either BAT5906 or Lucentis injections into the eye. T…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New syringe for eye disease injections passes usability test
Knowledge-focused CompletedThis study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Sam Chun Dang Pharm. Co. Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC